

Aimmune Therapeutics, Inc.
Form 4
August 11, 2015

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Longitude Capital Partners II, LLC

(Last) (First) (Middle)

800 EL CAMINO REAL, SUITE 220

(Street)

MENLO PARK, CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

Aimmune Therapeutics, Inc. [AIMT]

3. Date of Earliest Transaction (Month/Day/Year)

08/11/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___X___ 10% Owner
___ Officer (give title below) ___ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, \$0.0001 par value	08/11/2015		C		3,873,530	A	11 3,873,530
Common Stock, \$0.0001 par value	08/11/2015		C		3,248,600	A	11 7,122,130
Common Stock,	08/11/2015		P ⁽³⁾		312,500	A	\$ 16 7,434,630

By:
Longitude
Venture
Partners II,
L.P. ⁽²⁾

By:
Longitude
Venture
Partners II,
L.P. ⁽²⁾

By:
Longitude

Edgar Filing: Aimmune Therapeutics, Inc. - Form 4

\$0.0001
par value

Venture
Partners II,
L.P. ⁽²⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
					Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date Exercisable	Expiration Date			
				Code	V	(A)	(D)		Title	Amount Number Shares	
Series A Convertible Preferred Stock	<u>(1)</u>	08/11/2015		C		3,873,530		<u>(1)</u>	<u>(4)</u>	Common Stock	3,873,
Series B Convertible Preferred Stock	<u>(1)</u>	08/11/2015		C		3,248,600		<u>(1)</u>	<u>(4)</u>	Common Stock	3,248,

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Longitude Capital Partners II, LLC 800 EL CAMINO REAL SUITE 220 MENLO PARK, CA 94025		X		
Tammenoms Bakker Juliet C/O LONGITUDE CAPITAL PARTNERS II, LLC 800 EL CAMINO REAL, SUITE 220 MENLO PARK 94025		X		
Longitude Venture Partners II, L.P. C/O LONGITUDE CAPITAL PARTNERS II, LLC		X		

800 EL CAMINO REAL, SUITE 220
 MENLO PARK, CA 94025

ENRIGHT PATRICK G
 C/O LONGITUDE CAPITAL PARTNERS II, LLC X X
 800 EL CAMINO REAL, SUITE 220
 MENLO PARK, CA 94025

Signatures

LONGITUDE CAPITAL PARTNERS II, LLC, a Delaware limited liability company, By: /s/ Patrick G. Enright, Patrick G. Enright, Managing Member	08/11/2015
__Signature of Reporting Person	Date
LONGITUDE VENTURE PARTNERS II, L.P., By: Longitude Capital Partners II, LLC, a Delaware limited liability company, Its General Partner, By: /s/ Patrick G. Enright, Patrick G. Enright, Managing Member	08/11/2015
**Signature of Reporting Person	Date
/s/ Patrick G. Enright, Patrick G. Enright	08/11/2015
**Signature of Reporting Person	Date
/s/ Juliet Tammenoms Bakker, Juliet Tammenoms Bakker	08/11/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1 for 1 basis immediately prior to the closing of Issuer's initial public offering.
 This report is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital II as general partner of Longitude Venture II maybe
 (2) deemed to have sole voting, investment and dispositive power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are each managing members of Longitude Capital II and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by Reporting Persons. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.
- (3) Longitude Capital II purchased an additional 312,500 shares of Issuer's common stock in connection with the initial public offering at the offering price of \$16.00 per share.
- (4) The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock have no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.